Skip to content

Prime Medicine PRME Debt-to-equity

Debt-to-equity at other companies

Eli Lilly logo
Eli LillyLLY
1.4×-1.1×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
0.1×0.0×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
0.1×0.0×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
0.4×+0.3×
Beam Therapeutics logo
Beam TherapeuticsBEAM
0.2×+0.1×
Regenxbio logo
RegenxbioRGNX
3.4×+3.1×

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Current ratio3.8×-1.0×

Where this comes from

Calculated from Prime Medicine’s reported figures.

Based on the most recent quarter.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's debt-to-equity?
Prime Medicine (PRME) reported debt-to-equity of 1.5× in Q1 2026.
How has Prime Medicine's debt-to-equity changed year-over-year?
Prime Medicine's debt-to-equity increased by 31.8% year-over-year, from 1.1× to 1.5×.
What is the long-term trend for Prime Medicine's debt-to-equity?
Over 4 years (2020 to 2025), Prime Medicine's debt-to-equity has grown at a -4.4% compound annual growth rate (CAGR), from 1.2× to 1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.